Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 28, 2025Journal of Managed Care & Specialty Pharmacy

Health care resource utilization and direct costs incurred over 12 months by patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibodies: A US real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

OVOralee J. VarnadoBBBrenna L. BradyAZAnthony J. Zagar

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Varnado et al. (2025) studied this question.

synapsesocial.com/papers/6a99bcbc1d7d17f4cde2755ahttps://doi.org/10.18553/jmcp.2025.31.4.351
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial of Galcanezumab in Prevention of Episodic Cluster Headache2019 · 260 citations
  2. 2Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults2012 · 907 citations
  3. 3Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study2020 · 316 citations
  4. 4Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update2024 · 225 citations
  5. 5Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States2023 · 2 citations